# Metadata

- ID: 66f17aab821e116aacb2772d
- Domain: Single-Document QA
- Subdomain: Financial
- Difficulty: hard
- Length: medium

# Question

Which of the following is a highlight of Medtronic’s performance in fiscal year 2024?

# Choices

- A: The company’s stock performance exceeded the industry average.
- B: The company achieved growth in both revenue and profit.
- C: The company’s multiple new neuroscience products have received U.S. FDA approval, including the Inceptiv closed-loop rechargeable SCS, Symplicity Spyral renal denervation system, OsteoCool RF Tumor ablation system., and others.
- D: Driven by growth in international business, the company’s revenue achieved a growth.

# Answer

D
